# Institutional investment in Regeneron Pharmaceuticals > Live situation record from CLSTR: https://clstr.news/situations/institutional-investment-in-regeneron-pharmaceuticals > Updated: 2026-08-16T10:08:45.000Z. Sources: 2. Developments: 2. Regeneron Pharmaceuticals has experienced significant institutional investment and positive analyst outlooks. Early reports indicated that Carmignac Gestion increased its holding in the company by 133.3% during the first quarter, making it one of the fund’s largest holdings. Subsequent activity showed even larger-scale movements, with BlackRock Inc. acquiring approximately 9.1 million shares valued at roughly $5.68 billion during the second quarter, bringing its ownership to 8.62%. Other institutions, including Norges Bank and USA Financial Formulas, also established or increased positions. In tandem with this investment, market analysts have raised price targets for the company. Leerink Partners increased its target from $641.00 to $824.00, while other firms such as Cantor Fitzgerald and TD Cowen also adjusted their objectives upward, contributing to a consensus market rating of “Moderate Buy”. ## Timeline ### 2026-08-16: Regeneron Pharmaceuticals sees major institutional investment and analyst upgrades Regeneron Pharmaceuticals has attracted major institutional interest, including a $5.68 billion investment from BlackRock, while analysts at firms like Leerink Partners have raised price targets for the stock. 2 sources. https://clstr.news/cluster/regeneron-pharmaceuticals-sees-major-institutional-investment-and-analyst-upgrades ### 2026-08-02: Hedge Funds Adjust Stakes in Regeneron and Repligen Carmignac Gestion boosted its Regeneron stake by 133% to $90 M, while Perceptive Advisors cut its Repligen holding by 11% to $33 M. 2 sources. https://clstr.news/cluster/hedge-funds-adjust-stakes-in-regeneron-and-repligen --- Cite as: Institutional investment in Regeneron Pharmaceuticals. CLSTR, https://clstr.news/situations/institutional-investment-in-regeneron-pharmaceuticals